-+ 0.00%
-+ 0.00%
-+ 0.00%

Bristol Myers Squibb Reports Late-Stage Trial Results for Multiple Myeloma Drug

Benzinga·03/09/2026 11:04:22
Listen to the news

Bristol Myers Squibb (NYSE:BMY) today announced positive interim Phase 3 results from the SUCCESSOR-2 study (NCT05552976). In the trial, oral mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM). Safety findings were consistent with the known profile of mezigdomide and the combination regimen. Patients will continue to be followed for survival and safety.